OPTIMA:ATHEXOptima Bank SA Analysis
Data as of 2026-03-15 - not real-time
£182.50
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading beneath its short‑term, mid‑term and long‑term moving averages, confirming a bearish technical backdrop. RSI sits deep in oversold territory while the MACD histogram has turned positive, hinting at a potential short‑term bounce, and volume is on an upward trend despite elevated 30‑day volatility.
Valuation presents a mixed picture: the price‑to‑earnings multiple is comfortably below the sector average, yet the discounted cash‑flow model places fair value beneath the current price and the price‑to‑book ratio is extraordinarily high, while market sentiment leans toward greed.
Fundamentally, the company delivers robust revenue growth and a low PE relative to peers, but operates on thin margins, carries a high debt load, and does not pay a dividend. Analyst consensus is a strong buy with price targets substantially above the current level, suggesting upside potential if the technical and valuation pressures ease.
Valuation presents a mixed picture: the price‑to‑earnings multiple is comfortably below the sector average, yet the discounted cash‑flow model places fair value beneath the current price and the price‑to‑book ratio is extraordinarily high, while market sentiment leans toward greed.
Fundamentally, the company delivers robust revenue growth and a low PE relative to peers, but operates on thin margins, carries a high debt load, and does not pay a dividend. Analyst consensus is a strong buy with price targets substantially above the current level, suggesting upside potential if the technical and valuation pressures ease.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Oversold RSI indicating potential rebound
- Positive MACD histogram suggesting bullish momentum
- Increasing trading volume supporting short‑term interest
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong revenue growth but high leverage
- Valuation split between low PE and high DCF implied fair value
- Analyst target price implying upside but market sentiment already greedy
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustained revenue expansion in a stable healthcare niche
- Low PE relative to industry offering value appeal
- Positive analyst consensus with elevated target prices
Key Metrics & Analysis
Financial Health
Revenue Growth17.20%
Profit Margin3.10%
P/E Ratio15.2
ROE2.10%
ROA1.81%
Debt/Equity11.45
P/B Ratio95.6
Op. Cash Flow£9.8M
Free Cash Flow£5.4M
Industry P/E26.2
Technical Analysis
TrendBearish
RSI28.4
Support£177.00
Resistance£210.00
MA 20£184.90
MA 50£200.05
MA 200£205.71
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value£154.95
Target Price£243.50
Upside/Downside33.42%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.09
Volatility21.65%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.